API reference
Sodium zirconium cyclosilicate
- CAS number
- 17141-74-1
- Molecular formula
- Na2O9Si3Zr
- Molecular weight
- 365.45 g/mol
About this molecule
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. The treatment effect was maintained for up to 12 months.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- disodium;2,2,4,4,6,6-hexaoxido-1,3,5,2,4,6-trioxatrisilinane;zirconium(4+)
- InChIKey
- QMLIRKACNOVYNW-UHFFFAOYSA-N
- SMILES
- [O-][Si]1(O[Si](O[Si](O1)([O-])[O-])([O-])[O-])[O-].[Na+].[Na+].[Zr+4]
- PubChem CID
- 155804812
Also known as
UXSI-9 · Lokelma · Sodium Zirconium Cyclosilicate · Sodium zirconium silicate
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.